These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23886460)

  • 1. [Opiate substitution treatment's cycles in a five-year followed-up cohort in ambulatory practice].
    Dupouy J; Bez J; Barsony J; Oustric S; Lapeyre-Mestre M
    Therapie; 2013; 68(3):155-61. PubMed ID: 23886460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methadone and buprenorphine prescribing patterns of Victorian general practitioners: their first 5 years after authorisation.
    Longman C; Lintzeris N; Temple-Smith M; Gilchrist G
    Drug Alcohol Rev; 2011 Jul; 30(4):355-9. PubMed ID: 21355929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
    Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
    Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.
    Larance B; Degenhardt L; O'Brien S; Lintzeris N; Winstock A; Mattick RP; Bell J; Ali R
    Drug Alcohol Rev; 2011 Nov; 30(6):613-20. PubMed ID: 21355939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of drug tests in outpatients starting opioid substitution therapy.
    Dupouy J; Dassieu L; Bourrel R; Poutrain JC; Bismuth S; Oustric S; Lapeyre-Mestre M
    J Subst Abuse Treat; 2013; 44(5):515-21. PubMed ID: 23337248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine retention in primary care.
    Stein MD; Cioe P; Friedmann PD
    J Gen Intern Med; 2005 Nov; 20(11):1038-41. PubMed ID: 16307630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of opioid substitution therapy during medical intervention.
    Murnion B
    Intern Med J; 2012 Mar; 42(3):242-6. PubMed ID: 22432983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)].
    Fhima A; Henrion R; Lowenstein W; Charpak Y
    Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():IS26-36. PubMed ID: 11435992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of opioid substitution therapy utilisation among opioid-dependent men and women.
    Gisev N; Degenhardt L; Larney S; Larance B; Gibson A; Kimber J; Burns L
    Drug Alcohol Rev; 2014 Sep; 33(5):499-505. PubMed ID: 24840554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
    Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
    Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retention in Georgia opioid substitution therapy program and associated factors.
    Ruadze E; Todadze K
    Harm Reduct J; 2016 Dec; 13(1):35. PubMed ID: 27931232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy.
    Newman RG; Gevertz SG
    J Addict Dis; 2011 Oct; 30(4):318-22. PubMed ID: 22026523
    [No Abstract]   [Full Text] [Related]  

  • 13. Six-year mortality rates of patients in methadone and buprenorphine maintenance therapy: results from a nationally representative cohort study.
    Soyka M; Träder A; Klotsche J; Backmund M; Bühringer G; Rehm J; Wittchen HU
    J Clin Psychopharmacol; 2011 Oct; 31(5):678-80. PubMed ID: 21881461
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden.
    Richert T; Johnson B
    Harm Reduct J; 2015 Feb; 12():1. PubMed ID: 25889208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimising opioid substitution therapy in the prison environment.
    Alam F; Wright N; Roberts P; Dhadley S; Townley J; Webster R
    Int J Prison Health; 2019 Dec; 15(4):293-307. PubMed ID: 31532339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009.
    Welle-Strand GK; Skurtveit S; Jones HE; Waal H; Bakstad B; Bjarkø L; Ravndal E
    Drug Alcohol Depend; 2013 Jan; 127(1-3):200-6. PubMed ID: 22841456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Should I stay or should I go?" Coming off methadone and buprenorphine treatment.
    Winstock AR; Lintzeris N; Lea T
    Int J Drug Policy; 2011 Jan; 22(1):77-81. PubMed ID: 20956077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective.
    Johnson B; Richert T
    J Psychoactive Drugs; 2014; 46(5):427-35. PubMed ID: 25364995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid substitution treatment in pretrial prison detention: a case study from Geneva, Switzerland.
    Favrod-Coune T; Baroudi M; Casillas A; Rieder JP; Gétaz L; Barro J; Gaspoz JM; Broers B; Wolff H
    Swiss Med Wkly; 2013; 143():w13898. PubMed ID: 24186493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.